By Early 2016, GW Pharmaceuticals Could Get Approval From FDA

The drug, called Epidiolex, previously received fast-track status from the FDA and is now in the final Phase 3 study for pediatric epilepsy disorders, according to the Huffington Post. Results are expected in the first quarter of next year. Epidiolex is expected to “breeze through this final stage,” and it could be on the market... more →
Posted in: News

GW Pharmaceuticals Announces Appointment of Julian Gangolli to Board of Directors

GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the Company has appointed Julian Gangolli... more →
Posted in: Press

These Three Diseases Can Be Overcome With The Help Of Medical Pot

With this in mind, we asked three of our top health care analysts if there was a particular disease they believed marijuana had a shot at successfully fighting or even curing. Here’s what they had to say. : The evidence that GW Pharmaceuticals ‘ marijuana-derived drug, Epidiolex, works in epileptic patients isn’t... more →
Posted in: Investing

Marijuana’s Promise Of Profit Remains Difficult To Find For The Meantime

Regardless, investors should gain additional insight into Sativex’s efficacy in cancer pain soon. The first of three phase 3 trials for the indication is wrapping up this month, and that has GW Pharma telling investors that it will report data from the trial early next year. A second trial should offer up results before the... more →
Posted in: Investing

There’s Profit In Marijuana But Remains Elusive For The Meantime

Regardless, investors should gain additional insight into Sativex’s efficacy in cancer pain soon. The first of three phase 3 trials for the indication is wrapping up this month, and that has GW Pharma telling investors that it will report data from the trial early next year. A second trial should offer up results before the... more →
Posted in: Investing

It Is Still Risky To Invest In Marijuana Stocks

Contra Cramer, GW actually is a medical marijuana stock, sort of. Its whole business is based on cannabinoids, chemical compounds found in marijuana and hemp, as well as in the human body. They can also be produced synthetically. The company’s main product, Sativex, was developed to treat symptoms of multiple sclerosis, cancer,... more →
Posted in: Stocks